MX2009009520A - Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos. - Google Patents

Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos.

Info

Publication number
MX2009009520A
MX2009009520A MX2009009520A MX2009009520A MX2009009520A MX 2009009520 A MX2009009520 A MX 2009009520A MX 2009009520 A MX2009009520 A MX 2009009520A MX 2009009520 A MX2009009520 A MX 2009009520A MX 2009009520 A MX2009009520 A MX 2009009520A
Authority
MX
Mexico
Prior art keywords
arthritis
disease
cartilage
chronic
injury
Prior art date
Application number
MX2009009520A
Other languages
English (en)
Inventor
Dionisios Rentzeperis
Michael Gaul
Alexander Kim
Lily Lee Searle
Gilles C Bignan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39530136&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009520(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009009520A publication Critical patent/MX2009009520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), (ver fórmula I) métodos para preparar estos compuestos, composiciones, intermediarios y derivados de los mismos y para tratar una condición que incluye pero no limita la espondilitis anquilosante, aterosclerosis, artritis (tal como artritis reumatoide, artritis infecciosa, artritis de la niñez, artritis psoriática, artritis reactiva), enfermedades relacionadas con los huesos (incluyendo aquellas relacionadas con la formación de huesos), cáncer de mama (incluyendo aquellos que no responden a la terapia con antiestrógenos), trastornos cardiovasculares, enfermedades relacionadas con el cartílago (tal como lesión/pérdida de cartílago, degeneración de cartílago y aquellas relacionadas con la formación de cartílago), condrodisplacia, condrosarcoma, lesión crónica de columna, bronquitis crónica, enfermedad inflamatoria crónica de las vías aéreas, enfermedad pulmonar obstructiva crónica, diabetes, trastornos de la homeostasis de energía, gota, pseudo gota, trastornos de lípidos, síndrome metabólico, mieloma múltiple, obesidad, osteoartritis, osteogénesis imperfecta, metástasis ósea osteolítica, osteomalacia, osteoporosis, enfermedad de Paget, enfermedad periodontal, polimialgia reumática, síndrome de Reiter, lesión de estrés repetitivo, hiperglucemia, nivel elevado de glucosa en sangre y resistencia a la insulina.
MX2009009520A 2007-03-07 2008-03-06 Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos. MX2009009520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89346407P 2007-03-07 2007-03-07
PCT/US2008/056029 WO2008109737A1 (en) 2007-03-07 2008-03-06 Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators

Publications (1)

Publication Number Publication Date
MX2009009520A true MX2009009520A (es) 2009-11-18

Family

ID=39530136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009520A MX2009009520A (es) 2007-03-07 2008-03-06 Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos.

Country Status (17)

Country Link
US (1) US8580832B2 (es)
EP (1) EP2134698A1 (es)
JP (1) JP2010520308A (es)
KR (1) KR20090128454A (es)
CN (1) CN101679327A (es)
AR (1) AR065657A1 (es)
AU (1) AU2008222755B2 (es)
BR (1) BRPI0808776A2 (es)
CA (1) CA2680212A1 (es)
CL (1) CL2008000667A1 (es)
EA (1) EA016887B1 (es)
IL (1) IL200759A0 (es)
MX (1) MX2009009520A (es)
NZ (1) NZ579417A (es)
TW (1) TW200902506A (es)
UA (1) UA98484C2 (es)
WO (1) WO2008109737A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
RU2512283C2 (ru) 2008-11-28 2014-04-10 Янссен Фармасьютикалз, Инк. Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов
PT2430022E (pt) 2009-05-12 2013-12-26 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina e a sua utilização para o tratamento ou prevenção de doenças neurológicas e psiquiátricas
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20130040951A9 (en) * 2009-08-04 2013-02-14 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for cancer
WO2011019558A1 (en) * 2009-08-11 2011-02-17 Janssen Pharmaceutica Nv Methods to measure dissociation rates for ligands that form reversible covalent bonds
WO2011019556A1 (en) 2009-08-11 2011-02-17 Janssen Pharmaceutica Nv CO-CRYSTALLIZATION OF ERR-A α WITH A LIGAND THAT FORMS A REVERSIBLE CONVALENT BOND
WO2011075565A1 (en) * 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-Aα MODULATORS
TW201130831A (en) * 2010-02-17 2011-09-16 Janssen Pharmaceutica Nv Aminothiazolones as estrogen related receptor-alpha modulators
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
TW201311679A (zh) 2011-08-04 2013-03-16 Takeda Pharmaceutical 含氮雜環化合物
SG11201406032TA (en) 2012-03-26 2014-11-27 Nippon Chemiphar Co Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3050573B1 (en) 2013-09-25 2019-12-11 Nippon Chemiphar Co., Ltd. Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US20210032213A1 (en) 2019-03-28 2021-02-04 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x4 and related products and methods
US20220387401A1 (en) * 2019-07-04 2022-12-08 Lead Pharma Holding B.V. Estrogen-related receptor alpha modulators
CN112538038B (zh) * 2019-09-20 2022-05-20 暨南大学 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用
KR20220066822A (ko) 2020-11-16 2022-05-24 경북대학교 산학협력단 골 질환 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2006004555A1 (en) 2004-06-30 2006-01-12 Paysetter Pte Ltd System and method for facilitating transfer of physical money and/or credit
KR20070041560A (ko) * 2004-07-14 2007-04-18 얀센 파마슈티카 엔.브이. 에스트로겐 관련 수용체-알파 매개 질병 치료를 위한아릴리덴
AU2005299829B2 (en) * 2004-10-22 2011-09-08 Exelixis, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
CN101679327A (zh) 2010-03-24
JP2010520308A (ja) 2010-06-10
EA016887B1 (ru) 2012-08-30
AU2008222755B2 (en) 2013-05-02
IL200759A0 (en) 2010-05-17
UA98484C2 (ru) 2012-05-25
AR065657A1 (es) 2009-06-24
CA2680212A1 (en) 2008-09-12
WO2008109737A1 (en) 2008-09-12
KR20090128454A (ko) 2009-12-15
TW200902506A (en) 2009-01-16
CL2008000667A1 (es) 2008-11-03
BRPI0808776A2 (pt) 2014-08-19
US20080221179A1 (en) 2008-09-11
AU2008222755A1 (en) 2008-09-12
EA200970839A1 (ru) 2010-04-30
EP2134698A1 (en) 2009-12-23
US8580832B2 (en) 2013-11-12
NZ579417A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
MX2009009520A (es) Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos.
MX2009009517A (es) Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno.
MX2009009519A (es) Fenoxitiazolidinodionas n-alquiladas sustituidas como moduladores de receptor- alfa relacionados con estrogeno.
MX2012009529A (es) Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno.
MX2012009528A (es) Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno.
JP2010520308A5 (es)
JP2010520307A5 (es)
WO2005115383A3 (en) Substituted triazoles as modulators of ppar and methods of their preparation
JP2010520306A5 (es)
JP2012506473A5 (es)
WO2005115384A3 (en) Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
WO2014025406A1 (en) Dental materials and method of manufacture
WO2007077844A1 (ja) アルケニルを有するモノフッ素化テルフェニル化合物、液晶組成物および液晶表示素子
UA97975C2 (ru) ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛОВАННЫЕ ТИАЗОЛИДИНДИОНЫ КАК МОДУЛЯТОРЫ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α
Nguyen et al. Synthesis of the bio-based alternative to Bis-GMA and its application to photo-polymerizable adhesives
CN105602481B (zh) 一种本体型高强度仿生粘合剂的制备方法
MY160230A (en) Thermoplastic stiffening materials
CN110016124A (zh) 一种基于二苯砜的A-π-D-π-A型增感剂及其制备方法、应用
NO20076632L (no) Aktivator for peroksisomproliferator-aktivert receptor
Kálmán et al. Crystal and molecular structure of (+)-Carba-Thymidine, C11 H10 N2 O6
Satsangi et al. Synthesis of low‐shrinkage polymerizable methacrylate liquid‐crystal monomers
JP2017505765A5 (es)
Joshi et al. Further investigation on the nitration of BODIPY with cupric nitrate: crystal structures of 4, 4-difluoro-1, 3, 5, 7, 8-pentamethyl-2-nitro-4-bora-3a, 4a-diaza-s-indacene, 4, 4-difluoro-3-nitro-8-phenyl-4-bora-3a, 4a-diaza-s-indacene, and 3-chloro-6-ethyl-5, 7, 8-trimethyl-2-nitro-4, 4-diphenyl-4-bora-3a, 4a-diaza-s-indacene
Bredov et al. Methacrylate-containing polymer compounds for dentistry
JP2022056984A (ja) ラジカル重合性モノマーを溶媒とした医科歯科用低重合収縮性モノマーの合成・製造方法